N4 Pharma is pleased to announce the acquisition of a controlling interest, through a subscription for new ordinary shares, in Nanogenics Limited, a company with a complementary lipid and peptide-based delivery system called LipTide®, which it is using to develop a novel siRNA product targeting an unmet clinical need in the ophthalmology market.

The acquisition has been funded by a placing of 35,000,000 new ordinary shares of 0.4p each in the Company at an issue price of 1p per Placing Share raising £350,000 (before expenses).

A presentation on the acquisition and new technology is available to download here.

Watch the company update, presented by Nigel Theobald, CEO, N4 Pharma and Paul Murray, Executive Chairman, Nanogenics, followed by a Q&A session below.